Azitra Inc (AZTR) Stock Price, Quote & News

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular ras...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 646 6446

Website: azitrainc.com

Address:

21 Business Park Drive, Branford, United States

Kabita84 Nov. 14 at 9:37 PM

$AZTR

2 · Reply

pbacher Nov. 14 at 9:36 PM

$AZTR 13G/A This amendment refers to a Schedule 13G/A filed with the Securities and Exchange Commission on August 14, 2025, covering 1,521,492 shares of Common Stock underlying Warrants purchased on July 24, 2024. The amounts in Row (5), (7) and (9) include Common Stock underlying 273,497 Warrants. The percentage set forth on Row (11) of the cover page for the reporting person is based on 10,204,938 shares of Common Shares outstanding as of November 11, 2025, based upon the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12,

0 · Reply

Kabita84 Nov. 14 at 8:55 PM

$AZTR beginning of this week base line was 41 cents..end of this week you all are in 35 cents...next start with 35 cents ended to 30cents..

0 · Reply

Kabita84 Nov. 14 at 8:52 PM

$AZTR in 2 week this landed from .45 cents to .35..and float size raise from 5 millions to 10 millions..so u know than u know..next 2 weeks you can see this one landed to .28 cents...gradually dilution

0 · Reply

Kabita84 Nov. 14 at 4:14 PM

$AZTR lol

0 · Reply

davooo Nov. 14 at 2:53 PM

$AZTR Key Data Open$0.33 Day Range0.33 - 0.37 52 Week Range0.32 - 4.33 Market Cap$3.53M Shares Outstanding10.2M Public Float10.18M BetaN/A Rev. per EmployeeN/A P/E RatioN/A EPS-$5.49 YieldN/A DividendN/A Ex-Dividend DateN/A Short Interest1.32M 10/31/25 % of Float Shorted12.95% Average Volume4.87M

0 · Reply

pbacher Nov. 14 at 1:57 PM

$AZTR aaaand 100k more... great

0 · Reply

Kabita84 Nov. 14 at 1:44 PM

$AZTR company issues share in every stages..you wont see again 45 cents..like..if anyone bought 10k share company issues 10k from back hand..thats the thing going on now

1 · Reply

davooo Nov. 14 at 12:21 PM

$AZTR 10 million shares outstanding now 😳

1 · Reply

_SquidGains_ Nov. 13 at 11:39 PM

$AZTR $LNZA $ENTO $VTAK 🏝️

0 · Reply

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Nov 7, 2025, 6:00 AM EST - 7 days ago

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Oct 20, 2025, 8:02 AM EDT - 25 days ago

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Oct 3, 2025, 4:45 PM EDT - 6 weeks ago

Azitra Receives Notice of Non-Compliance from NYSE American

Sep 4, 2025, 8:10 AM EDT - 2 months ago

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:10 AM EDT - 2 months ago

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Aug 22, 2025, 6:01 AM EDT - 3 months ago

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

IVV SPXL SPY SSO UPRO VOO ZM

Aug 11, 2025, 5:00 PM EDT - 3 months ago

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Aug 11, 2025, 4:15 PM EDT - 3 months ago

Azitra, Inc. Announces Reverse Stock Split

Jun 17, 2025, 8:02 AM EDT - 5 months ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 10, 2025, 8:33 AM EDT - 5 months ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

May 28, 2025, 8:33 AM EDT - 6 months ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 14, 2025, 4:05 PM EDT - 6 months ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 13, 2025, 5:06 PM EDT - 6 months ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Apr 25, 2025, 8:33 AM EDT - 7 months ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 24, 2025, 4:05 PM EDT - 7 months ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Mar 12, 2025, 8:33 AM EDT - 8 months ago

Azitra to Present at Microbiome Times Partnering Forum

Feb 24, 2025, 8:30 AM EST - 9 months ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 4, 2025, 2:20 PM EST - 10 months ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 3, 2025, 9:05 AM EST - 10 months ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Jan 27, 2025, 4:05 PM EST - 10 months ago

Azitra, Inc. to Present at The Microcap Conference

Jan 15, 2025, 8:30 AM EST - 10 months ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 10 months ago

Azitra Announces Proposed Public Offering of Common Stock

Nov 12, 2024, 5:05 PM EST - 1 year ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024

Oct 11, 2024, 9:00 AM EDT - 1 year ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 20, 2024, 4:15 PM EDT - 1 year ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 12, 2024, 6:23 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Jul 25, 2024, 5:57 PM EDT - 1 year ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Jul 25, 2024, 1:54 PM EDT - 1 year ago

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

HAL

Jul 25, 2024, 1:13 PM EDT - 1 year ago

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

HAL

Jul 23, 2024, 9:20 PM EDT - 1 year ago

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

May 31, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

May 17, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

May 10, 2024, 8:00 AM EDT - 1 year ago

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

May 9, 2024, 5:00 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Mar 15, 2024, 4:15 PM EDT - 1 year ago

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Feb 16, 2024, 4:05 PM EST - 1 year ago

Azitra, Inc. Announces Closing of Public Offering

Feb 13, 2024, 10:09 PM EST - 1 year ago

Azitra, Inc. Announces Pricing of Public Offering

Jan 16, 2024, 9:00 AM EST - 1 year ago

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Jan 3, 2024, 9:00 AM EST - 2 years ago

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

Nov 14, 2023, 4:30 PM EST - 2 years ago

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

Kabita84 Nov. 14 at 9:37 PM

$AZTR

2 · Reply

pbacher Nov. 14 at 9:36 PM

0 · Reply

Kabita84 Nov. 14 at 8:55 PM

$AZTR beginning of this week base line was 41 cents..end of this week you all are in 35 cents...next start with 35 cents ended to 30cents..

0 · Reply

Kabita84 Nov. 14 at 8:52 PM

0 · Reply

Kabita84 Nov. 14 at 4:14 PM

$AZTR lol

0 · Reply

davooo Nov. 14 at 2:53 PM

0 · Reply

pbacher Nov. 14 at 1:57 PM

$AZTR aaaand 100k more... great

0 · Reply

Kabita84 Nov. 14 at 1:44 PM

$AZTR company issues share in every stages..you wont see again 45 cents..like..if anyone bought 10k share company issues 10k from back hand..thats the thing going on now

1 · Reply

davooo Nov. 14 at 12:21 PM

$AZTR 10 million shares outstanding now 😳

1 · Reply

_SquidGains_ Nov. 13 at 11:39 PM

$AZTR $LNZA $ENTO $VTAK 🏝️

0 · Reply

Kabita84 Nov. 13 at 10:32 PM

$AZTR

1 · Reply

Kabita84 Nov. 13 at 8:24 PM

$AZTR if i want i can make this drop to below 30 cents..at this moment..very easy to do..i prefer to do after hours..so we can see below 20 cents...

4 · Reply

pbacher Nov. 13 at 7:45 PM

$AZTR new atl incoming. Unbelievable

0 · Reply

pbacher Nov. 13 at 3:46 PM

$AZTR oh yes. makes sense. from plus 5 percent to red with no volume.

1 · Reply

Alnumani Nov. 13 at 2:43 PM

$AZTR

0 · Reply

pbacher Nov. 13 at 1:26 PM

$AZTR

1 · Reply

Kevin73ca Nov. 13 at 5:28 AM

$AZTR Discord and Reddit snd market makers can make this highlight Once volume starts easy 50 percent to 100 percent up

0 · Reply

Kevin73ca Nov. 13 at 5:26 AM

$AZTR Overnight

0 · Reply

OG80 Nov. 13 at 12:46 AM

$AZTR https://finviz.com/news/228043/azitra-inc-announces-q3-2025-results-and-provides-business-updates

0 · Reply

f84 Nov. 12 at 11:10 PM

$AZTR Absolutely awful 10Q. They have barely raised enough cash for a single quarter despite the massive P&Ds (which I thought Alumni was using to sell its shares bought from Azitra). They still need to raise a lot just to get to their P1 readout.

0 · Reply

Bulltrader988 Nov. 12 at 10:44 PM

$AZTR 👃👀 https://www.stocktitan.net/news/AZTR/azitra-inc-announces-q3-2025-results-and-provides-business-jonuuewg4wm4.html

0 · Reply

Omarzaid Nov. 12 at 10:26 PM

$AZTR https://ir.azitrainc.com/news-releases/news-release-details/azitra-inc-announces-q3-2025-results-and-provides-business

0 · Reply

Market Cap	1.43M
Revenue (ttm)	10,000.00
Net Income (ttm)	-8.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89,700.00%
Debt to Equity Ratio	0.00

Volume	386,100
Avg Vol	3,165,392
Day's Range	N/A - N/A
Shares Out	3.53M
Stochastic %K	11%
Beta	-1.71
Analysts	Strong Sell
Price Target	$4.50